Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
6(50%)
Results Posted
100%(5 trials)

Phase Distribution

Ph phase_4
2
17%
Ph phase_3
10
83%

Phase Distribution

0

Early Stage

0

Mid Stage

12

Late Stage

Phase Distribution12 total trials
Phase 3Large-scale testing
10(83.3%)
Phase 4Post-market surveillance
2(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

6

trials recruiting

Total Trials

12

all time

Status Distribution
Active(6)
Completed(5)
Terminated(1)

Detailed Status

Recruiting6
Completed5
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
6
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 310 (83.3%)
Phase 42 (16.7%)

Trials by Status

recruiting650%
completed542%
withdrawn18%

Recent Activity

6 active trials
Showing 5 of 12
completedphase_3

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05061719
recruitingphase_3

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

NCT06229210
recruitingphase_3

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

NCT06372964
recruitingphase_3

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05850689
recruitingphase_3

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

NCT06462586
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05061719Phase 3

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Completed
NCT06229210Phase 3

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

Recruiting
NCT06372964Phase 3

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

Recruiting
NCT05850689Phase 3

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Recruiting
NCT06462586Phase 3

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

Recruiting
NCT06462612Phase 3

Study of Lumateperone in the Treatment of Patients With Bipolar Mania

Recruiting
NCT06174116Phase 4

Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

Recruiting
NCT05061706Phase 3

Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Completed
NCT04985942Phase 3

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Completed
NCT04285515Phase 3

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Completed
NCT05890768Phase 4

Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

Withdrawn
NCT03249376Phase 3

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12